drugset
drugset / Trial / NCT05508204

Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

NCT05508204 ↗

Phase 1 Completed 36 enrolled Chinook Therapeutics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1, open-label study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic of multiple doses of BION-1301 in Japanese healthy subjects.

Timeline

Start
2022-07-19
Primary completion
2022-12-16
Completion
2022-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject zigakibart Monoclonal antibody — Subcutaneous

Indications

No indication recorded.